Inhibition of Histone Deacetylase Increases Cytotoxicity to Anticancer Drugs Targeting DNA

Cancer Research

Volumn 63, Issue 21, 2003, Pages 7291-7300

  Kim, Myoung Sook ^a   Blake, Mellissa ^a   Baek, Jin Hyen ^b   Kohlhagen, Glenda ^c   Pommier, Yves ^c   Carrier, France ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ELLIPTICINE; ETOPOSIDE; FLUOROURACIL; GYRASE INHIBITOR; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; BRAIN TUMOR; CANCER CELL CULTURE; CELL KILLING; CHROMATIN; CHROMATIN STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DNA PROTEIN COMPLEX; DRUG ACETYLATION; DRUG EFFICACY; DRUG TARGETING; ENZYME INHIBITION; EPITHELIUM CELL; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SENSITIZATION;

ACETYLATION; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; ETOPOSIDE; GENE EXPRESSION; GLIOBLASTOMA; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0242610850     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Capranico, G., Jaxel, C., Roberge, M., Kohn, K. W., and Pommier, Y. Nucleosome positioning as a critical determinant for the DNA cleavage sites of mammalian DNA topoisomerase II in reconstituted simian virus 40 chromatin. Nucleic Acids Res., 18: 4553-4559, 1990.
2. Wang, J. C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell. Biol., 3: 430-440, 2002.
3. Pommier, Y. DNA topoisomerase II inhibitors. In: B. A. Teicher (ed.) Cancer Therapeutics: Experimental and Clinical Agents, pp. 153-174. Totowa, NJ: Humana Press, 1997.
4. Chen, A. Y., and Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34: 191-218, 1994.
5. D'Arpa, P., Beardmore, C., and Liu, L. F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res., 50: 6919-6924, 1990.
6. Verreault, A. De novo nucleosome assembly: new pieces in an old puzzle. Genes Dev., 14: 1430-1438, 2000.
7. Kas, E., Poljak, L., Adachi, Y., and Laemmli, U. K. A model for chromatin opening: stimulation of topoisomerase II and restriction enzyme cleavage of chromatin by distamycin. EMBO J., 12: 115-126, 1993.
8. Fesen, M., and Pommier, Y. Mammalian topoisomerase II activity is modulated by the DNA minor groove binder distamycin in simian virus 40 DNA. J. Biol. Chem., 264: 11354-11359, 1989.
9. Varga-Weisz, P. D., Blank, T. A., and Becker, P. B. Energy-dependent chromatin accessibility and nucleosome mobility in a cell-free system. EMBO J., 14: 2209-2216, 1995.
10. Kingston, R. E., Bunker, C. A., and Imbalzano, A. N. Repression and activation by multiprotein complexes that alter chromatin structure. Genes Dev., 10: 905-920, 1996.
11. Bradbury, E. M. Reversible histone modifications and the chromosome cell cycle. Bioessays, 14: 9-16, 1992.
12. Lee, D. Y., Hayes, J. J., Pruss, D., and Wolffe, A. P. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell, 72: 73-84, 1993.
13. Piepmeier, J. M., Rabidou, N., Schold, S. C., Jr., Bitonti, A. J., Prakash, N. J., and Bush, T. L. In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor. Cancer Res., 56: 359-361, 1996.
14. Kohn, K. W., Ewig, R. A. G., Erickson, L. C., and Zwelling, L. A. Measurement of strand breaks and cross-links by alkaline elution. In: E. C. Friedberg and P. C. Hanawalt (eds.) DNA Repair: A Laboratory Manual of Research Procedures, pp. 379-401. New York: Marcel Dekker Inc., 1981.
15. Carrier, F., Georgel, P. T., Pourquier, P., Blake, M., Kontny, H. U., Antinore, M. J., Gariboldi, M., Myers, T. G., Weinstein, J. N., Pommier, Y., and Fornace, A. J., Jr. Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin. Mol. Cell. Biol., 19: 1673-1685, 1999.
16. Jayaraman, L., and Prives, C. Covalent and noncovalent modifiers of the p53 protein. Cell Mol. Life Sci., 55: 76-87, 1999.
17. Herzog, C. E., Zwelling, L. A., McWatters, A., and Kleinerman, E. S. Expression of topoisomerase II, bcl-2, and p53 in three human brain tumor cell lines and their possible relationship to intrinsic resistance to etoposide. Clin. Cancer Res., 1: 1391-1397, 1995.
18. Yoshida, M., Kijima, M., Akita, M., and Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by tnchostatin A. J. Biol. Chem., 265: 17174-17179, 1990.
19. Minucci, S., Horn, V., Bhattacharyya, N., Russanova, V., Ogryzko, V. V., Gabriele, L., Howard, B. H., and Ozato, K. A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc. Natl. Acad. Sci. USA, 94: 11295-11300, 1997.
20. Hebbes, T. R., Clayton, A. L., Thome, A. W., and Crane-Robinson, C. Core histone hyperacetylation co-maps with generalized DNase 1 sensitivity in the chicken β-globin chromosomal domain. EMBO J., 13: 1823-1830, 1994.
21. Capranico, G., Binaschi, M., Borgnetto, M. E., Zunino, F., and Palumbo, M. A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons. Trends Pharmacol. Sci., 18: 323-329, 1997.
22. Munster, P. N., Troso-Sandoval, T., Rosen, N., Rifkind, R., Marks, P. A., and Richon, V. M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res., 61: 8492-8497. 2001.
23. Adachi, N., Nomoto, M., Kohno, K., and Koyama, H. Cell-cycle regulation of the DNA topoisomerase IIα promoter is mediated by proximal CCAAT boxes: possible involvement of acetylation. Gene (Amst.), 245: 49-57, 2000.
24. Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J. E., Lee, S. W., Moon, E. J., Kim, H. S., Lee, S. K., Chung, H. Y., Kim, C. W., and Kim, K. W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med., 7: 437-443, 2001.
25. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345-347, 1991.
26. Yoshida, M., Horinouchi, S., and Beppu, T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays, 17: 423-430, 1995.
27. Amundson, S. A., Myers, T. G., and Fornace, A. J., Jr. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene. 17: 3287-3299, 1998.
28. Wang, Y., Rea, T., Bian, J., Gray, S., and Sun, Y. Identification of the genes responsive to etoposide-induced apoptosis: application of DNA chip technology. FEBS Lett., 445, 269-273, 1999.
29. Xiao, H., Hasegawa, T., Miyaishi, O., Ohkusu, K., and Isobe, K. Sodium butyrate induces NIH3T3 cells to senescence-like state and enhances promoter activity of p21WAF/CIP1 in p53-independent manner. Biochem. Biophys. Res. Commun. 237: 457-460, 1997.
30. Arriola, E. L., Lopez, A. R., and Chresta, C. M. Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. Oncogene, 18: 1081-1091. 1999.
31. Solary, E., Bertrand, R., and Pommier, Y. Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. Leuk. Lymphoma, 15: 21-32, 1994.
32. Fan, J., and Bertino, J. R. Modulation of cisplatinum cytotoxicity by p53: effect of p53-mediated apoptosis and DNA repair. Mol. Pharmacol., 56: 966-972, 1999.
33. Kessis, T. D., Slebos, R. J., Nelson, W. G., Kastan, M. B., Plunkett, B. S., Han, S. M., Lorincz, A. T., Hedrick, L., and Cho, K. R. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA, 90: 3988-3992, 1993.
34. Nitiss, J. L., and Nitiss K. C. Resistance to topoisomerase-targeting agents. In: J. R. Bertino (ed.), Encyclopedia of Cancer, 2nd ed., Vol. 4, pp. 129-141. New York: Academic Press. 2002.
35. Tsai, S. C., Valkov, N., Yang, W. M., Gump, J., Sullivan, D., and Seto, E. Histone deacetylase interacts directly with DNA topoisomerase II. Nat. Genet., 26: 349-353, 2000.
36. Gupta, M., Fujimori, A., and Pommier, Y. Eukaryotic DNA topoisomerases I. Biochim. Biophys. Acta, 1262: 1-14, 1995.
37. Marks, P. A., Richon, V. M., Breslow, R., and Rifkind, R. A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol., 13: 477-483, 2001.
38. Nelson, W. G., and Kastan, M. B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815-1823, 1994.
39. 1 arrest. Proc. Natl. Acad. Sci. USA, 93: 4827-4832. 1996.
40. Richter, A., and Ruff, J. DNA topoisomerase 1 cleavage sites in DNA and in nucleoprotein complexes, Biochemistry, 30: 9741-9748, 1991.
41. Johnson, C. A., Padget, K., Austin, C. A., and Turner, B. M. Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis. J. Biol. Chem., 276: 4539-4542. 2001.
42. Lanza, A., Tomaletti, S., Rodolfo, C., Scanavini, M. C., and Pedrini, A. M. Human DNA topoisomerase I-mediated cleavages stimulated by ultraviolet light-induced DNA damage. J. Biol. Chem., 271: 6978-6986, 1996.
43. Pourquier, P., Pilon, A. A., Kohlhagen, G., Mazumder, A., Sharma, A., and Pommier, Y. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. J. Biol. Chem., 272: 26441-26447, 1997.
44. Udvardy, A., and Schedl, P. Chromatin structure, not DNA sequence specificity, is the primary determinant of topoisomerase II sites of action in vivo. Mol. Cell. Biol., 11: 4973-4984, 1991.
45. Varga-Weisz, P. D., Wilm, M., Bonte, E., Dumas, K., Mann, M., and Becker, P. B. Chromatin-remodelling factor CHRAC contains the ATPases ISWI and topoisomerase 11. Nature (Lond.), 388: 598-602, 1997.
46. Ellis, A. L., and Zwelling, L. A. Resistance to topoisomerase II directed anticancer agents. In: J. A. Hickman and T. R. Tritton (eds.), Cancer Chemotherapy, pp. 200-212. Oxford, United Kingdom: Blackwell Scientific Publications. 1993.
47. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 849-852. 1993.
48. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W. W., Owen-Schaub, L. B., and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54: 2287-2291, 1994.
49. Shono, T., Tofilon, P. J., Schaefer, T. S., Parikh, D., Liu, T. J., and Lang, F. F. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Cancer Res., 62: 1069-1076. 2002.
50. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., Jr., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents, Cancer Res., 57: 4285-4300. 1997.
51. Kastan, M. B., Zhan, Q., el-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71: 587-597, 1992.
52. Ishii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A. C., and Van Meir, E. G. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol., 9: 469-479. 1999.
53. Wang, J., Shou, J., and Chen, X. Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53. Oncogene. 19: 1843-1848, 2000.
54. Zhan, Q., Bae, I., Kastan, M. B., and Fornace, A. J., Jr. The p53-dependent γ-ray response of GADD45. Cancer Res., 54: 2755-2760, 1994.
55. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63: 1129-1136, 1990.
56. Murphy, M., Ahn, J., Walker, K. K., Hoffman, W. H., Evans, R. M., Levine. A. J., and George, D. L. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev., 13: 2490-2501, 1999.